Capromorelin

I’ll be honest — when I first came across capromorelin, I almost skipped right past it. A growth hormone secretagogue that got dropped from human trials and ended up as a dog appetite pill? Not exactly the headline that makes a biohacker’s heart race.

But the more I dug into the research, the more interesting the story got. There’s a real Phase II human trial with nearly 400 elderly adults. There’s solid data on lean body mass. And the ghrelin receptor pathway it targets? That’s one of the most fascinating intersections of appetite, growth hormone, sleep, and — potentially — cognition in all of neuroscience.

The catch is that “potentially” is doing a lot of heavy lifting in that sentence. Let me break down what we actually know versus what’s still speculation.

The Short Version: Capromorelin is an oral ghrelin receptor agonist that stimulates growth hormone release and appetite. A human trial showed modest gains in lean body mass and physical function in elderly adults, but the results weren’t impressive enough for Pfizer to continue development. It’s now only FDA-approved for dogs and cats. If you’re interested in oral GH secretagogues, MK-677 (ibutamoren) is the more practical and better-studied choice for humans.

What Is Capromorelin?

Capromorelin is a synthetic, non-peptide small molecule that mimics the hormone ghrelin — often called “the hunger hormone.” Developed by Pfizer in the early 2000s, it belongs to the pyrazolinone-piperidine dipeptide class of growth hormone secretagogues. Its molecular formula is C₂₈H₃₅N₅O₄, and the standard pharmaceutical form is the tartrate salt.

The compound was originally designed to tackle a real problem: age-related frailty. As we age, growth hormone levels decline, contributing to muscle loss, reduced physical function, and decreased quality of life. Pfizer saw an opportunity — what if you could boost GH levels with a simple oral pill instead of expensive injections?

They ran a legitimate Phase II clinical trial. Published in the Journal of Clinical Endocrinology & Metabolism in 2009, the White et al. study enrolled 395 adults aged 65–84 who were at risk for functional decline. The plan was a two-year study. They pulled the plug after one year. The results were statistically significant but clinically modest — not the blockbuster outcome a pharmaceutical company needs to justify the massive expense of Phase III trials.

After human development was abandoned around 2017, capromorelin found its second life in veterinary medicine. It’s now FDA-approved as Entyce (for appetite stimulation in dogs) and Elura (for weight management in cats with chronic kidney disease). It’s actually the only FDA-approved ghrelin receptor agonist for animal use — which is a distinction that matters more to your dog than to you.

How Does Capromorelin Work?

Think of your pituitary gland as a factory that produces growth hormone. That factory has two different doorbells. One is the GHRH receptor — that’s the “please start making growth hormone” button. The other is the ghrelin receptor (GHS-R1a) — that’s the “make MORE growth hormone RIGHT NOW” amplifier button.

Capromorelin rings that second doorbell. Hard.

When capromorelin binds to GHS-R1a receptors on pituitary somatotroph cells, it triggers a signaling cascade through Gα₁₁ proteins that causes a burst of growth hormone release. This GH then travels to the liver, where it stimulates production of insulin-like growth factor 1 (IGF-1) — the downstream messenger responsible for many of GH’s effects on muscle growth, tissue repair, and metabolism.

But here’s where it gets more interesting for the nootropics crowd. GHS-R1a receptors aren’t just in the pituitary. They’re scattered throughout the brain, including the hypothalamus and hippocampus. In the hypothalamus, ghrelin receptor activation flips on orexigenic (appetite-stimulating) pathways — which is why ghrelin makes you hungry and why capromorelin works so well as an appetite stimulant in animals.

In the hippocampus — the brain’s memory center — ghrelin receptor activation promotes synaptic incorporation of AMPA receptors, enhances long-term potentiation (LTP), and supports neurogenesis. In plain English: activating this receptor appears to help your brain form and strengthen memories.

Reality Check: Those cognitive benefits come from ghrelin receptor research as a class — primarily using ghrelin itself or other agonists in animal models. No one has run a cognitive study with capromorelin specifically. The leap from “ghrelin receptors in the hippocampus do cool things” to “capromorelin makes you smarter” is a bridge that hasn’t been built yet.

One major advantage capromorelin has over native ghrelin: you can swallow it. Ghrelin is a peptide that gets destroyed in the gut, requiring injection. Capromorelin has solid oral bioavailability — roughly 65% in rats and 44% in dogs. It absorbs fast too, hitting peak blood levels in about 50 minutes with a short half-life of approximately 1.2 hours.

Benefits of Capromorelin

Let’s tier the evidence honestly, because the quality varies dramatically depending on what benefit we’re talking about.

What the Human Trial Actually Showed

The White et al. Phase II trial is the crown jewel — and the only substantial human dataset. In 395 elderly adults taking capromorelin for up to 12 months:

• Lean body mass increased by +1.4 kg at 6 months and +1.6 kg at 12 months compared to placebo, measured by DEXA scan. That’s roughly 3.5 pounds of lean mass — meaningful for an elderly population at risk of sarcopenia, but not exactly bodybuilder territory.
• Total body weight increased by +1.4 kg at 6 months versus a slight weight loss in the placebo group.
• Physical function improved. Tandem walk times got better at both 6 and 12 months. Stair climbing power improved at 12 months.
• IGF-1 levels rose in a sustained, dose-dependent manner across all treatment groups.

These results are real. They’re from a well-designed, placebo-controlled trial. But they were also deemed insufficient to continue development — which tells you something about the magnitude of benefit.

Promising but Unproven in Humans

Sleep quality: Ghrelin promotes slow-wave sleep — the deep, restorative phase where your body releases most of its natural GH. Research with ghrelin itself shows enhanced delta-wave activity when administered near sleep onset. Capromorelin’s short half-life and GH-boosting effects suggest it could enhance sleep quality with evening dosing, but this hasn’t been tested directly.

Neuroprotection and cognition: Animal studies with ghrelin receptor agonists show improved performance in water maze and novel object recognition tests, enhanced hippocampal LTP, and protective effects against amyloid-beta pathology. These are class-level findings — interesting, but not capromorelin-specific data.

Insider Tip: If the cognitive angle is what draws you to ghrelin receptor agonists, keep your eye on the broader research field rather than capromorelin specifically. The ghrelin-hippocampus connection is a legitimate area of neuroscience research that may eventually yield practical applications.

Robust Veterinary Evidence

Capromorelin reliably stimulates appetite and promotes weight gain in dogs and cats — with a wide safety margin (dogs tolerated 17.5x the label dose for 12 months). This isn’t directly translatable to humans, but it confirms the compound does what it’s supposed to do mechanistically.

How to Take Capromorelin

Let me be upfront: there is no established human dosing protocol for capromorelin. Human trials were discontinued, and no regulatory agency has approved it for human use. Everything below is drawn from the clinical trial data for informational purposes.

The White et al. trial tested four dosing regimens:

• 10 mg three times per week
• 3 mg twice daily
• 10 mg nightly
• 10 mg twice daily

Here’s the counterintuitive finding: the least frequent dosing schedule (10 mg three times per week) produced the greatest peak nocturnal growth hormone rise. More frequent dosing appeared to cause some degree of receptor desensitization — your body’s way of turning down the volume when the signal keeps blaring.

Timing matters. Given capromorelin’s rapid absorption (peak levels in ~50 minutes) and short half-life (~1.2 hours), evening dosing makes the most physiological sense. It aligns with your body’s natural nocturnal GH pulse and could theoretically complement ghrelin’s sleep-promoting effects.

Food interactions: Glucose and insulin suppress GH release. Taking capromorelin with a carbohydrate-heavy meal would likely blunt its effects. The same principle applies to all GH secretagogues — take them on an empty stomach or with minimal food.

Pro Tip: If you’re exploring GH secretagogues and this “take it infrequently for better results” finding surprises you, the same pattern shows up with other ghrelin agonists. The GHS-R1a receptor is prone to desensitization with continuous stimulation. Less can genuinely be more with this class of compounds.

The standard pharmaceutical form is capromorelin tartrate. It’s available from research chemical suppliers like Sigma-Aldrich and Cayman Chemical at ≥98% purity, though these are sold strictly for research use.

Side Effects and Safety

The human trial data gives us a reasonable safety picture, though from only 12 months of exposure.

Commonly reported side effects:

• Fatigue
• Insomnia (somewhat ironic given ghrelin’s sleep-promoting reputation)
• Nausea and bloating
• Decreased blood pressure

The glucose concern is the big one. Capromorelin produced small but measurable increases in fasting glucose and HbA1c levels. Hyperglycemia was reported in 4.77% of treated patients versus 1.24% on placebo. The investigators described the insulin resistance changes as “of minimal clinical consequence,” but this is a class effect of ghrelin agonists that deserves attention — especially with longer-term use.

Important: If you have diabetes, prediabetes, or impaired glucose tolerance, ghrelin receptor agonists are a poor fit. They decrease glucose-stimulated insulin secretion and may worsen glycemic control. This applies to capromorelin, MK-677, and the entire class.

Other contraindications:

• Active malignancy — GH/IGF-1 axis stimulation could theoretically promote tumor growth. No direct evidence with capromorelin, but it’s a well-established class concern.
• Pregnancy and nursing — no human safety data exists. Avoid.

Drug interactions to watch:

• Insulin and diabetes medications (opposing effects on glucose)
• Other GH secretagogues like MK-677 or GHRP-6 (additive effects, unknown safety profile)
• Somatostatin analogs like octreotide (would work against capromorelin’s mechanism)

No formal human drug interaction studies have been published, which is another reminder of how early this compound’s human development was when it stopped.

Stacking Capromorelin

Since capromorelin works through the ghrelin receptor (GHS pathway), it pairs theoretically well with compounds that work through the complementary GHRH pathway. This GHRH + GHS synergy is well-established in growth hormone pharmacology.

Potentially synergistic combinations:

• Sermorelin or CJC-1295: These GHRH analogs stimulate GH synthesis and release through a different receptor. Combining GHRH + GHS pathways produces greater GH pulses than either alone. The trade-off: sermorelin and CJC-1295 require injection.
• Melatonin: May enhance nocturnal GH secretion and complement ghrelin’s sleep-promoting effects. A low-risk addition.
• L-Arginine and L-Ornithine: Amino acids that support GH release partly through suppression of somatostatin (GH’s “off switch”).

What NOT to combine:

• MK-677 (ibutamoren): Both are oral ghrelin receptor agonists targeting the same receptor. Combining them is redundant, not synergistic, and would likely increase side effects — particularly glucose dysregulation.
• Exogenous growth hormone: Defeats the purpose of a secretagogue by suppressing your body’s natural GH pulsatility.
• High-carbohydrate meals around dosing: Insulin spikes suppress GH release and would blunt capromorelin’s effects.

My Take

Here’s my honest assessment: capromorelin is a historically interesting compound that has almost no practical relevance for the nootropics community right now.

The science behind the ghrelin receptor is genuinely fascinating. The fact that one receptor pathway ties together appetite, growth hormone release, sleep architecture, and hippocampal memory formation — that’s beautiful biology. And capromorelin proved that you can hit this pathway with an oral pill and get real, measurable results in humans.

But the results were modest. Modest enough that Pfizer — a company with essentially unlimited resources — walked away. And when a pharmaceutical giant decides the juice isn’t worth the squeeze, that’s a signal worth paying attention to.

If you’re interested in oral GH secretagogues, MK-677 (ibutamoren) is the clear practical choice. It has a longer half-life, vastly more human research data, a massive user experience base, and is actually available from research peptide vendors. Capromorelin offers no meaningful advantage over MK-677 for the self-experimenter.

If you’re drawn to the cognitive and neuroprotective angle of ghrelin receptor agonism, I’d focus on established nootropics with direct human cognitive data — Lion’s Mane for nerve growth factor, Bacopa Monnieri for memory consolidation, or Phosphatidylserine for cognitive maintenance. The ghrelin-cognition research is promising at the basic science level, but we’re years away from that translating into a practical supplement recommendation.

The one group I’d keep this on the radar for? People following GH secretagogue research closely who want to understand the full landscape of the field. Capromorelin’s human trial data is a useful reference point, and the “less frequent dosing = better GH response” finding has implications for how people use MK-677 and other ghrelin agonists.

For everyone else? File this one under “interesting science, limited practical application” and focus on the fundamentals — sleep, gut health, stress management, and compounds with stronger human evidence behind them.